Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.

被引：0
|
作者：
Kay-Oliver Kliche
Konstantin Kubsch
Martin Raida
Rami Masri-Zada
Klaus Höffken
机构：
[1] Department of Internal Medicine II,
[2] Friedrich-Schiller University,undefined
[3] Erlanger Allee 101,undefined
[4] 07740 Jena,undefined
[5] Germany,undefined
[6] Department of Internal Medicine I,undefined
[7] Friedrich-Schiller University,undefined
[8] Jena,undefined
[9] Germany,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2002年 / 128卷
关键词：
Chronotherapy Colorectal cancer Oxaliplatin Irinotecan Sodium folinate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Abstract
引用
收藏
页码：516 / 524
页数：8
相关论文
共 50 条
  • [21] Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL).
    Aparicio, A
    Iqbal, S
    Yang, D
    Groshen, S
    Park, D
    Garcia, A
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 312S - 312S
  • [22] Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
    Modest, Dominik Paul
    Heinemann, Volker
    Schuett, Philipp
    Angermeier, Stefan
    Haberkorn, Mike
    Waidmann, Oliver
    Graeven, Ullrich
    Wille, Kai
    Kunzmann, Volker
    Henze, Larissa
    Constantin, Christian
    de Wit, Maike
    Denzlinger, Claudio
    Ballhausen, Alexej
    Kurreck, Annika
    Jelas, Ivan
    Alig, Annabel Helga Sophie
    Stahler, Arndt
    Stintzing, Sebastian
    Oettle, Helmut
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (07)
  • [23] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
    Cavanna, Luigi
    Artioli, Fabrizio
    Codignola, Claudio
    Lazzaro, Antonio
    Rizzi, Anna
    Gamboni, Alessandro
    Rota, Luigina
    Rodino, Carmelina
    Boni, Fabrizio
    Iop, Aldo
    Zaniboni, Alberto
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 371 - 375
  • [24] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Folprecht, Gunnar
    Hamann, Susanne
    Schuete, Katharina
    Trarbach, Tanja
    Stoehlmacher-Williams, Jan
    Ehninger, Gerhard
    BMC CANCER, 2014, 14
  • [25] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Gunnar Folprecht
    Susanne Hamann
    Katharina Schütte
    Tanja Trarbach
    Jan Stoehlmacher-Williams
    Gerhard Ehninger
    BMC Cancer, 14
  • [26] Optimal circadian time of vinorelbine (V) combined with chronomodulated 5-FU in pretreated metastatic breast cancer patients.: EORTC 05971 randomized multicenter study.
    Coudert, B.
    Focan, C.
    Genet, D.
    Giacchetti, S.
    Lentz, M.
    Marreaud, S.
    Baron, B.
    Gorlia, T.
    Lévi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 95S - 95S
  • [27] FOLFIRINOX versus sequential 5-FU, oxaliplatin, and irinotecan-based regimens in patients with recurrent pancreatic cancer (rPDAC).
    Rehman, Hasan
    Chi, Jeffrey
    Hakim, Nausheen
    Jose, Jyothi
    Moriarty, Linda
    Lamont, Carol
    Saif, Wasif M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] GEMCITABINE (GEM) PLUS OXALIPLATIN, FOLINIC ACID (FA) AND 5-FLUOROURACIL (5-FU) IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Correale, Pierpaolo
    Fulfaro, Fabio
    Cicero, Giuseppe
    Bajardi, Emilio
    Marsili, Stefania
    Petrioli, Roberto
    Vuolo, Giuseppe
    Guarnieri, Alfredo
    Gebbia, Nicola
    Francini, Guido
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 71
  • [29] Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC).
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Bernuzzi, P
    Bertè, R
    Bidin, L
    Palladino, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 330S - 330S
  • [30] Cetuximab plus capecitabine (CAP) and oxaliplatin (LOHP) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after combination chemotherapy including oxaliplatin, irinotecan (CPT-11), and 5-fluorouracil (5-FU) or capecitabine
    Souglakos, J
    Androulakis, N
    Kalykaki, A
    Saridaki, Z
    Vardakis, N
    Kalbakis, K
    Agelaki, S
    Vamvakas, L
    Kentepozidis, N
    Giassas, S
    Mavroudis, D
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41
12345